Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.60 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.60 |
| ▸ | SMO | Q99835 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348090 | 0.87 | CYP11B1 (0.57) | CYP11B1CYP11B2SMOMAOBKDM4E | |
| SCHEMBL1363389 | 0.86 | CYP11B1 (0.69) | CYP11B1CYP11B2SMONR3C1 | |
| SCHEMBL9986667 | 0.83 | SMO (0.49) | CYP11B1CYP11B2SMOMAPK1NR3C1 | |
| SCHEMBL30040852 | 0.83 | SMO (0.49) | CYP11B1CYP11B2SMOMAPK1NR3C1 | |
| SCHEMBL25228277 | 0.82 | SMO (0.48) | CYP11B1CYP11B2SMOMAPK1KDM4E | |
| SCHEMBL17942269 | 0.82 | CYP11B1 (0.55) | CYP11B1CYP11B2SMOMAPK1NR3C1 | |
| SCHEMBL836030 | 0.81 | CYP11B1 (0.56) | CYP11B1CYP11B2SMOHTTMAOB | |
| SCHEMBL31632962 | 0.80 | CYP11B2 (0.65) | CYP11B1CYP11B2SMOFGFR1HPGD | |
| SCHEMBL30204271 | 0.79 | ALOX15 (0.50) | CYP11B1CYP11B2CYP19A1ALOX15HTT | |
| SCHEMBL24976359 | 0.78 | CYP11B1 (0.47) | CYP11B1CYP11B2SMOMAPK1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117858877-A | C-linked inhibitors of ENL/AF9 YEATS | 桥梁药品有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230027198-A1 | INHIBITORS OF ENL/AF9 YEATS | THE ROCKEFELLER UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| US-20230027198-A1 | INHIBITORS OF ENL/AF9 YEATS | THE ROCKEFELLER UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| CN-115427035-A | ENL/AF9YEATS inhibitors | 洛克菲勒大学 | 2022-12-02 | — | — | CN | disclosed |
| EP-4076440-A1 | INHIBITORS OF ENL/AF9 YEATS | The Rockefeller University (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021127166-A1 | INHIBITORS OF ENL/AF9 YEATS | THE ROCKEFELLER UNIVERSITY (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127166-A1 | INHIBITORS OF ENL/AF9 YEATS | THE ROCKEFELLER UNIVERSITY (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027198-A1 | INHIBITORS OF ENL/AF9 YEATS | MLLT3, YEATS2, MLLT1 | CYP11B1 4547/4885CYP11B2 4616/4885SMO 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.